Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome is a research paper published in Journal of Cellular and Molecular Medicine (2022). On theSindex it has a DataRank of 0.449. It has been cited 19 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.449
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Agencia Estatal de Investigación
Grant: PID2019‐110755RB‐I00/AEI/10.13039/501100011033
Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya
Grant: 2017 SGR 926
Fundació la Marató de TV3
Grant: 2016/20‐30
Generalitat de Catalunya
Grant: CERCA Programme
Horizon 2020 Framework Programme
Grant: 848077
Gene overdosage and comorbidities during the early lifetime in Down Syndrome
Ministerio de Ciencia e Innovación
Grant: EMBL Partnership
NIH Blueprint for Neuroscience Research
Grant: 1R01EB 028159‐01
NIBIB NIH HHS
Grant: R01 EB028159
Jerôme Lejeune Foundation
Grant: 2002
Agencia Estatal de Investigación
Grant: PID2019-110755RB-I00/AEI/10.13039/501100011033
Fundació la Marató de TV3
Grant: 2016/20-30
EU Joint Programme - Neurodegenerative Disease Research
Grant: AC170006
National Institutes of Health
Grant: 1R01EB028159-01
New methods and theories to interrogate organizational principles from single cell to neuronal networks
FWCI
2.71
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals